2020
Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy.
Eldirany SA, Ho M, Bunick CG. Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. The Yale Journal Of Biology And Medicine 2020, 93: 19-27. PMID: 32226331, PMCID: PMC7087057.Peer-Reviewed Original ResearchConceptsBiologic therapyTumor necrosis factor alphaFirst-line treatmentTreatment of psoriasisNecrosis factor alphaClinical responseInterleukin-17Interleukin-23Line treatmentPrescribing practicesPsoriasis therapyInflammatory disordersTreatment optionsTherapeutic decisionsClinical dataFactor alphaPatient safetyTherapySignificant differencesBiologic medicinesDrugsEpitope locationMolecular differencesTreatmentMedicationsEfficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Van Voorhees A, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. Journal Of The American Academy Of Dermatology 2020, 83: 96-103. PMID: 32032692, DOI: 10.1016/j.jaad.2020.01.072.Peer-Reviewed Original ResearchConceptsSevere scalp psoriasisNumeric rating scaleItch Numeric Rating ScaleDermatology Life Quality IndexSafety of apremilastScalp psoriasisPhase 3bWeek 16Inadequate response/intolerancePhysician Global Assessment responseCommon adverse eventsPhysician global assessmentPlacebo-controlled studySevere plaque psoriasisDouble-blind studyProportion of patientsLife Quality IndexPruritic areaPlaque psoriasisPrimary endpointSecondary endpointsAdverse eventsMore patientsMild diseasePsoriasis therapy
2019
Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index
Elnabawi YA, Oikonomou EK, Dey AK, Mancio J, Rodante JA, Aksentijevich M, Choi H, Keel A, Erb-Alvarez J, Teague HL, Joshi AA, Playford MP, Lockshin B, Choi AD, Gelfand JM, Chen MY, Bluemke DA, Shirodaria C, Antoniades C, Mehta NN. Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index. JAMA Cardiology 2019, 4: 885-891. PMID: 31365032, PMCID: PMC6669789, DOI: 10.1001/jamacardio.2019.2589.Peer-Reviewed Original ResearchConceptsPerivascular fat attenuation indexFat attenuation indexBiologic psoriasis therapyBiologic therapyCoronary inflammationSevere psoriasisPsoriasis therapyCoronary plaquesSkin diseasesAnti-tumor necrosis factor αChronic inflammatory skin diseaseDifferent biologic agentsTraditional risk scoresCoronary plaque burdenLow cardiovascular riskProspective cohort studyAnti-inflammatory effectsCoronary artery diseaseInflammatory skin diseaseCoronary atherosclerotic plaquesNecrosis factor αSevere skin diseaseCardiovascular eventsCardiovascular riskCohort study
2018
Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative
Perez-Chada LM, Cohen JM, Gottlieb AB, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF. Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. Archives Of Dermatological Research 2018, 310: 701-710. PMID: 30167814, DOI: 10.1007/s00403-018-1855-3.Peer-Reviewed Original ResearchConceptsInternational Dermatology Outcome MeasuresPsA symptomsPsoriasis clinical trialsPsoriatic arthritisClinical trialsHealth Measurement INstruments (COSMIN) guidelinesPatient Index DataPsoriatic Arthritis ImpactInternational Dermatology Outcome Measures (IDEOM) initiativeRole of PSAMost study participantsPatient GlobalArthritis ImpactPsoriasis therapyOutcome measuresTrial participantsRAPID3SymptomsStudy participantsArthritisRCTsResponsive measurePSAMost participantsTrialsCARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris
Craiglow BG, Boyden LM, Hu R, Virtanen M, Su J, Rodriguez G, McCarthy C, Luna P, Larralde M, Humphrey S, Holland KE, Hogeling M, Hidalgo-Matlock B, Ferrari B, Fernandez-Faith E, Drolet B, Cordoro KM, Bowcock AM, Antaya RJ, Ashack K, Ashack RJ, Lifton RP, Milstone LM, Paller AS, Choate KA. CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. Journal Of The American Academy Of Dermatology 2018, 79: 487-494. PMID: 29477734, PMCID: PMC6098739, DOI: 10.1016/j.jaad.2018.02.034.Peer-Reviewed Original ResearchConceptsPityriasis rubra pilarisPapulosquamous eruptionPsoriasis therapyFamily historyCARD14 mutationsRegistry of subjectsFeatures of psoriasisSystemic psoriasis therapiesSpectrum of diseaseDisorders of keratinizationWhole-exome sequencingOral retinoidsClinical characteristicsClinical featuresClinical historyTumor necrosisDiagnostic uncertaintyFamilial pityriasis rubra pilarisProminent involvementPsoriasisGenetic testingHeterozygous mutationsExome sequencingMinimal responseSmall sample size
2016
Clinical meaningfulness of complete skin clearance in psoriasis
Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P. Clinical meaningfulness of complete skin clearance in psoriasis. Journal Of The American Academy Of Dermatology 2016, 75: 77-82.e7. PMID: 27206759, DOI: 10.1016/j.jaad.2016.03.026.Peer-Reviewed Original ResearchConceptsComplete skin clearanceSkin clearancePASI 100Score 0Dermatology Life Quality IndexNew psoriasis therapiesPsoriasis Symptom InventoryTotal skin clearancePercentage of patientsPhase III trialsHealth-related qualityLife Quality IndexMeaningful end pointsPASI 75PASI 90Psoriasis symptomsPsoriasis therapyTreatment responsePatient's perspectiveInsufficient evidenceClinical meaningfulnessPatientsEnd pointSymptom InventoryClearance
2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1
Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatology And Therapy 2012, 2: 1. PMID: 23205324, PMCID: PMC3510391, DOI: 10.1007/s13555-012-0001-y.Peer-Reviewed Original ResearchDifficult treatment scenariosPsoriatic nail diseaseSevere scalp psoriasisSystemic lupus erythematosusOptimal treatment optionsDelphi consensus approachField of psoriasisAnogenital dysplasiaConcomitant psoriasisCardiovascular morbiditySevere psoriasisOlder patientsScalp psoriasisTopical therapyLupus erythematosusPsoriasis therapyChallenging patientsHuman papillomaTreatment optionsClinical trialsConsensus panelNail diseasePsoriasisTreatment approachesClinical scenarios
2009
A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach
Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. Journal Of The American Academy Of Dermatology 2009, 61: s1-s46. PMID: 19527820, DOI: 10.1016/j.jaad.2009.03.017.Peer-Reviewed Original ResearchConceptsTreatment optionsSevere psoriasisAvailable evidence-based dataHistory of malignancyEfficacious treatment optionBreast-feeding womenMedical treatment optionsSystemic psoriasis therapiesEvidence-based dataDelphi consensus approachLatent tuberculosisPsoriatic diseaseLiver diseasePsoriasis therapyHealthy patientsTreatment recommendationsClinical trialsCardiovascular diseaseConsensus panelViral infectionPatientsOptimum managementDisease statesMedical evidenceDisease
2007
National Psoriasis Foundation Clinical Consensus on Disease Severity
Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ. National Psoriasis Foundation Clinical Consensus on Disease Severity. JAMA Dermatology 2007, 143: 239-242. PMID: 17310004, DOI: 10.1001/archderm.143.2.239.Peer-Reviewed Original ResearchConceptsNational Psoriasis Foundation Medical BoardConsensus statementSeverity criteriaClinical practiceClinical consensus statementTask ForceCategory of patientsNational Psoriasis FoundationCurrent clinical practiceMedical boardsPlaque psoriasisSevere psoriasisAppropriate therapyPsoriasis therapyClinical consensusInsurance payerDisease severityPsoriasisPatientsCurrent standardTherapyMedical professionalsSeverityExpert opinionMDThe use of therapeutic interchange for biologic therapies.
Flood J, Mihalik C, Fleming R, Strober B, Zucker D, Burgoyne D. The use of therapeutic interchange for biologic therapies. Managed Care 2007, 16: 51-62. PMID: 17285813.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsProton pump inhibitorsBiologic agentsTherapeutic interchangeRheumatoid arthritisBiologic therapyHMG-CoA reductase inhibitorsSerotonin reuptake inhibitorsPopulation-based outcomesHealth care professionalsMode of administrationOverall treatment costsTolerability profileAppropriate therapyReuptake inhibitorsPsoriasis therapyPump inhibitorsDrug classesIndividual patientsCare professionalsNew agentsEnzyme inhibitorsPatientsReductase inhibitorsTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply